JP5417662B2 - ネビラピンの徐放性製剤 - Google Patents
ネビラピンの徐放性製剤 Download PDFInfo
- Publication number
- JP5417662B2 JP5417662B2 JP2009552940A JP2009552940A JP5417662B2 JP 5417662 B2 JP5417662 B2 JP 5417662B2 JP 2009552940 A JP2009552940 A JP 2009552940A JP 2009552940 A JP2009552940 A JP 2009552940A JP 5417662 B2 JP5417662 B2 JP 5417662B2
- Authority
- JP
- Japan
- Prior art keywords
- nevirapine
- tablet
- hypromellose
- max
- sustained release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 title claims description 109
- 229960000689 nevirapine Drugs 0.000 title claims description 52
- 239000000203 mixture Substances 0.000 title claims description 37
- 238000013268 sustained release Methods 0.000 title claims description 20
- 239000012730 sustained-release form Substances 0.000 title claims description 20
- 238000009472 formulation Methods 0.000 title description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229960003943 hypromellose Drugs 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 229920003130 hypromellose 2208 Polymers 0.000 claims description 7
- 229940031707 hypromellose 2208 Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 5
- 229960001021 lactose monohydrate Drugs 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 229920003125 hypromellose 2910 Polymers 0.000 claims description 3
- 229940031672 hypromellose 2910 Drugs 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims 2
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000003672 processing method Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940098802 viramune Drugs 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Description
(a)1,000〜2,300ng/mLの幾何平均Cmax、および
(b)73,400〜178,100ng・h/mLの幾何平均AUC0-∞によって
ならびに、400mgのネビラピンを含む剤形では、次の2つのパラメーター:
(a)1,210〜2,740ng/mLの幾何平均Cmax、および
(b)109,000〜237,000ng・h/mLの幾何平均AUC0-∞によって特徴付けられる、特有の薬物動態プロフィールを示す。
300mg用量の場合は
(a)2,300〜3,700ng/mLの幾何平均Cmax,ss、および
(b)45,000〜75,000ng・h/mLの幾何平均AUC0-24h,ssによって、
400mg用量の場合は
(a)3,100〜4,900ng/mLの幾何平均Cmax,ss、および
(b)60,000〜99,000ng・h/mLの幾何平均AUC0-24h,ssによって特徴付けられる。
(a)400mgの無水ネビラピン;
(b)270mgのヒプロメロース2208(Methocel(商標)K4M Premium CR);
(c)400mgの乳糖一水和物;および
(d)10mgのステアリン酸マグネシウム
を含有する医薬錠剤であり、ここで、各錠剤は、約10〜25kNの力で圧縮される。
乳糖、ネビラピン薬物、およびヒプロメロースを、混合し、次いで水を用いて完全に顆粒化する。次いで、顆粒を乾燥する。乾燥した顆粒を、製粉し、滑沢剤(ステアリン酸マグネシウム)と一緒にして混合し、錠剤に圧縮するための最終混合物を調製する。錠剤は、約10〜25kNの力で9.3×19.0mmの錠剤に圧縮される。
乳糖、ネビラピン薬物、およびヒプロメロースを、混合し、次いで水を用いて完全に顆粒化する。次いで、顆粒を乾燥する。乾燥した顆粒を、製粉し、滑沢剤(ステアリン酸マグネシウム)と一緒にして混合し、錠剤に圧縮するための最終混合物を調製する。錠剤は、約10〜25kNの力で9.3×19.0mmの錠剤に圧縮される。
乳糖、ネビラピン薬物、およびヒプロメロースを、混合し、次いで水を用いて完全に顆粒化する。次いで、顆粒を乾燥する。乾燥した顆粒を、製粉し、滑沢剤(ステアリン酸マグネシウム)と一緒にして混合し、錠剤に圧縮するための最終混合物を調製する。錠剤は、9.3×19.0mmの錠剤に圧縮される。
乳糖、ネビラピン薬物、およびヒプロメロースを、混合し、次いで水を用いて完全に顆粒化する。次いで、顆粒を乾燥する。乾燥した顆粒を、製粉し、滑沢剤(ステアリン酸マグネシウム)と一緒にして混合し、錠剤に圧縮するための最終混合物を調製する。錠剤は、約10〜25kNの力で9.3×19.0mmの錠剤に圧縮される。
実施例1、2、3および4で説明した5種の製剤の溶出プロフィールを図4に示す。示した溶出情報は、下記の試験方法によって得られた。
米国薬局方のパドル法は、例えば米国薬局方XXII(1990)中に記載されているパドル法である。
溶出パラメーター:
・媒体容積:900mL
・温度:37.3℃
・回転速度:50rpm
・サンプリング時点:最初の4時間は30分毎、次いで1時間毎(4〜24時間)
・無限大回転:250rpmで15分間
・オンラインフィルター:10μmの全流式フィルター(VanKel社、ノースカロライナ州Cary;またはQuality Lab Accessories L.L.S.)
Claims (6)
- (a)20重量%〜25重量%のヒプロメロースを含む徐放性マトリックス中に300mgのネビラピンを含み、かつ絶食しているヒトに単回投与として投与された場合に、
(1)1,000〜2,300ng/mLの幾何平均Cmax;および
(2)73,400〜178,100hr(ng/mL)の幾何平均AUC0-∞を示し、ヒトに多回投与で投与された場合に、
(1)2,300〜3,700ng/mLの幾何平均Cmax,ss;および
(2)45,000〜75,000hr(ng/mL)の幾何平均AUC0-24,ssを示す;あるいは
(b)20重量%〜25重量%のヒプロメロースを含む徐放性マトリックス中に400mgのネビラピンを含み、かつ絶食しているヒトに単回投与として投与された場合に、
(1)1,210〜2,740ng/mLの幾何平均Cmax;および
(2)109,000〜237,000hr(ng/mL)の幾何平均AUC0-∞を示し、ヒトに多回投与で投与された場合に、
(1)3,100〜4,900ng/mLの幾何平均Cmax,ss;および
(2)60,000〜99,000hr(ng/mL)の幾何平均AUC0-24,ssを示す、錠剤の形態の医薬組成物であって、
(a)及び(b)の両組成物が10時間〜48時間の絶食単回投与Tmaxを示し、多回投与中に測定して1.1〜2の範囲であるCmax,ss/Cmin,ssを示す、医薬組成物。 - 徐放性マトリックス中にネビラピンを含む医薬組成物であって、該組成物が、溶出を、米国薬局方のパドル法を使用して、50rpmで、6%w/wのラウリル硫酸ナトリウムを含む、容積が900mLでpHが6.8の水性緩衝液で、37℃で測定した場合に、2時間の時点で2%w/w以上30%w/w以下のネビラピンが放出され;8時間の時点で20%w/w以上100%w/w以下のネビラピンが放出され;14時間の時点で40%w/w以上100%w/w以下のネビラピンが放出されるようなインビトロでの溶出プロフィールを有する、請求項1記載の医薬組成物。
- 各錠剤が、
(a)400mgの無水ネビラピン;
(b)270mgのヒプロメロース2208;
(c)400mgの乳糖一水和物;および
(d)10mgのステアリン酸マグネシウム
を含有し、
各錠剤が10〜25kNの力で圧縮される、請求項1又は2記載の錠剤型医薬剤形。 - 各錠剤が、
(a)400mgの無水ネビラピン;
(b)202.50mg及び270mgから選択される量のヒプロメロース2208又は2910;
(c)400mgの乳糖一水和物;および
(d)10mgのステアリン酸マグネシウム
を含有し、
各錠剤が10〜25kNの力で圧縮される、請求項1又は2記載の錠剤型医薬剤形。 - 各錠剤が、
(a)400mgの無水ネビラピン;
(b)270mgのヒプロメロース2208;
(c)400mgの乳糖一水和物;および
(d)10mgのステアリン酸マグネシウム
を含有し、
各錠剤が10〜25kNの力で圧縮される、請求項1記載の錠剤型医薬剤形。 - 各錠剤が、
(a)300mgの無水ネビラピン;
(b)151.875mg及び202.50mgから選択される量のヒプロメロース2208又は2910;
(c)300mgの乳糖一水和物;および
(d)7.50mgのステアリン酸マグネシウム
を含有し、
各錠剤が10〜25kNの力で圧縮される、請求項1又は2記載の錠剤型医薬剤形。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94276507P | 2007-06-08 | 2007-06-08 | |
US60/942,765 | 2007-06-08 | ||
PCT/US2008/065705 WO2008154234A2 (en) | 2007-06-08 | 2008-06-04 | Extended release formulation of nevirapine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010520891A JP2010520891A (ja) | 2010-06-17 |
JP5417662B2 true JP5417662B2 (ja) | 2014-02-19 |
Family
ID=39739795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009552940A Active JP5417662B2 (ja) | 2007-06-08 | 2008-06-04 | ネビラピンの徐放性製剤 |
Country Status (29)
Country | Link |
---|---|
US (1) | US8460704B2 (ja) |
EP (1) | EP2155169B1 (ja) |
JP (1) | JP5417662B2 (ja) |
KR (1) | KR101017862B1 (ja) |
CN (1) | CN101784263B (ja) |
AR (1) | AR066924A1 (ja) |
AU (1) | AU2008262031B2 (ja) |
BR (1) | BRPI0811732A2 (ja) |
CA (1) | CA2687491C (ja) |
CL (1) | CL2008001678A1 (ja) |
CO (1) | CO6150128A2 (ja) |
DK (1) | DK2155169T3 (ja) |
EA (1) | EA018377B1 (ja) |
EC (1) | ECSP099561A (ja) |
ES (1) | ES2574836T3 (ja) |
HK (1) | HK1145806A1 (ja) |
HU (1) | HUE028598T2 (ja) |
IL (1) | IL199924A0 (ja) |
MA (1) | MA31430B1 (ja) |
MX (1) | MX2009007764A (ja) |
NZ (1) | NZ578664A (ja) |
PE (2) | PE20090371A1 (ja) |
PL (1) | PL2155169T3 (ja) |
TN (1) | TN2009000510A1 (ja) |
TW (1) | TWI419716B (ja) |
UA (1) | UA97971C2 (ja) |
UY (1) | UY31128A1 (ja) |
WO (1) | WO2008154234A2 (ja) |
ZA (1) | ZA200904939B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
ES2574836T3 (es) | 2007-06-08 | 2016-06-22 | Boehringer Ingelheim International Gmbh | Formulación de liberación prolongada de nevirapina |
CA2953975C (en) | 2008-06-27 | 2019-11-26 | Duke University | Therapeutic agents comprising elastin-like peptides |
EP2714045A1 (en) | 2011-05-30 | 2014-04-09 | Cipla Limited | Pharmaceutical antiretroviral composition |
WO2013028989A1 (en) * | 2011-08-24 | 2013-02-28 | Phasebio Pharmaceuticals, Inc. | Formulations of active agents for sustained release |
EP2822560A1 (en) * | 2012-03-05 | 2015-01-14 | Cipla Limited | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine |
CN104523630B (zh) * | 2015-01-22 | 2017-08-25 | 山东新时代药业有限公司 | 一种奈韦拉平片剂 |
EP3153157A1 (en) | 2015-10-09 | 2017-04-12 | Teva Pharmaceutical Works Private Limited Company | Pharmaceutical composition for prolonged release of nevirapine |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366972A (en) * | 1989-04-20 | 1994-11-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
US5419917A (en) * | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
US6514530B2 (en) * | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
AU1534699A (en) * | 1997-12-05 | 1999-06-28 | Alza Corporation | Osmotic dosage form comprising first and second coats |
ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
IL145661A0 (en) * | 1999-03-31 | 2002-06-30 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
EA005423B1 (ru) * | 1999-09-24 | 2005-02-24 | Янссен Фармацевтика Н.В. | Противовирусные композиции |
US20020071863A1 (en) | 1999-12-09 | 2002-06-13 | Dong Liang C. | Antiviral medication |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
WO2002092095A1 (en) | 2001-05-11 | 2002-11-21 | Boehringer Ingelheim International Gmbh | Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine |
US20030050620A1 (en) | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
WO2004043435A2 (en) | 2002-11-13 | 2004-05-27 | Control Delivery Systems, Inc. | Systemic delivery of antiviral agents |
WO2004112724A2 (en) | 2003-06-20 | 2004-12-29 | Viral Genomix, Inc. | Compositions for and methods for treating hiv |
CN1863512A (zh) | 2003-10-01 | 2006-11-15 | 鲁宾有限公司 | 控释药物组合物及其制备方法 |
ATE460901T1 (de) | 2003-11-13 | 2010-04-15 | Psivida Inc | Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut |
CA2577288C (en) * | 2004-09-02 | 2010-11-30 | Janssen Pharmaceutica N.V. | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
US20110104267A1 (en) * | 2005-04-25 | 2011-05-05 | Aurobindo Pharma Limited | Pharmaceutical compositions of antiretrovirals |
JP2009500318A (ja) | 2005-06-29 | 2009-01-08 | パナセア バイオテック リミテッド | 新規な徐放性医薬組成物とその製法 |
EP1906937B1 (en) | 2005-07-22 | 2016-10-19 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
CA2625776A1 (en) | 2005-10-14 | 2007-04-26 | Microdose Technologies, Inc. | Pharmaceutical packaging of an oral dosage combination |
ES2574836T3 (es) | 2007-06-08 | 2016-06-22 | Boehringer Ingelheim International Gmbh | Formulación de liberación prolongada de nevirapina |
-
2008
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/en not_active Revoked
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active IP Right Grant
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/en active Application Filing
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-04 CA CA2687491A patent/CA2687491C/en active Active
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
-
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown
-
2011
- 2011-01-05 HK HK11100032.7A patent/HK1145806A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5417662B2 (ja) | ネビラピンの徐放性製剤 | |
ES2205000T3 (es) | Composicion farmaceutica que contiene irbesartan. | |
JP6043281B2 (ja) | 4−アミノ−5−フルオロ−3−[6−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]−1h−キノリン−2−オンラクテート一水和物を含む医薬組成物 | |
JP6122639B2 (ja) | インテグラーゼ阻害剤を含有する固形医薬組成物 | |
US20090088424A1 (en) | Methods and compositions for controlling the bioavailability of poorly soluble drugs | |
WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
JP2023071921A (ja) | 様々な用量のレナリドミドの経口用錠剤組成物 | |
CN110913843B (zh) | 药物组合物 | |
WO2020122244A1 (ja) | 錠剤及びその製造方法 | |
JP2021518422A (ja) | レナリドミドを含む医薬組成物 | |
WO2019004871A1 (ru) | Фармацевтическая композиция, обладающая активностью против вич-инфекции | |
WO2018202224A1 (en) | Film-coated tablets of deferasirox | |
RU2603469C2 (ru) | Таблетка с контролируемым высвобождением для перорального введения и способ ее приготовления | |
TWI595871B (zh) | 含有兒茶酚-o-甲基轉移酶抑制劑之口服醫藥組成物及其製造方法 | |
EP3335703A1 (en) | Pharmaceutical composition comprising omarigliptin | |
EP3900708A1 (en) | Extended-release medical composition containing zaltoprofen | |
WO2023128898A1 (en) | Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients | |
WO2023149546A1 (ja) | 経口固形製剤 | |
WO2021253681A1 (zh) | 一种法匹拉韦组合物及其制备方法 | |
WO2013100876A1 (en) | Risperidone formulations | |
EP3383402A1 (en) | Pharmaceutical composition comprising darunavir and method for the preparation thereof | |
NZ760868B2 (en) | A solid oral fixed dose composition comprising metformin, valsartan and atorvastatin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120717 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121016 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130325 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130725 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131028 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131101 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5417662 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |